Top Next Generation Cancer Diagnostics Companies

Next Generation Cancer Diagnostics Market size was valued at USD 13.66 Billion in 2023 and is poised to grow from USD 16.09 Billion in 2024 to USD 50.68 Billion by 2032, growing at a CAGR of 17.8% during the forecast period (2025-2032).

These companies are involved in the development, manufacturing, and commercialization of a range of next-generation cancer diagnostic technologies and tests, including liquid biopsies, NGS, and imaging techniques. The market is characterized by intense competition, with companies competing on the basis of product features, quality, pricing, and customer service. 'Abbott Laboratories (US) ', 'Agilent Technologies, Inc. (US) ', 'Bio-Rad Laboratories, Inc. (US) ', 'Danaher Corporation (US) ', 'Exact Sciences Corporation (US) ', 'F. Hoffmann-La Roche Ltd. (Switzerland) ', 'GE Healthcare (US) ', 'Guardant Health, Inc. (US) ', 'Hologic, Inc. (US) ', 'Illumina, Inc. (US) ', 'Merck & Co., Inc. (US) ', 'Myriad Genetics, Inc. (US) ', 'NanoString Technologies, Inc. (US) ', 'Natera, Inc. (US) ', 'NeoGenomics, Inc. (US) ', 'Qiagen N.V. (Netherlands) ', 'Quest Diagnostics Incorporated (US) ', 'Siemens Healthineers AG (Germany) ', 'Sysmex Corporation (Japan) ', 'Thermo Fisher Scientific, Inc. (US) ', 'Veracyte, Inc. (US)'

The rising demand for personalized medicines is another factor driving the growth of the next generation cancer diagnostics market. Personalized medicine involves tailoring treatments to individual patients based on their genetic profile and other characteristics. Next generation cancer diagnostics tools can help identify patients who are most likely to benefit from personalized treatments.

Liquid biopsy tests have emerged as a promising alternative to traditional tissue biopsy tests for cancer diagnosis and treatment monitoring. These tests involve the analysis of a patient's blood, urine, or other bodily fluids to detect cancer cells and other biomarkers. Liquid biopsy tests are less invasive and less expensive than traditional biopsy tests, and they can provide more frequent and accurate results. As a result, there has been a growing adoption of liquid biopsy tests in the market, with several companies investing in the development of these tests.

The largest market is expected to be in North America in 2023 and for the duration of the forecast. High per capita healthcare spending and supportive healthcare policies are responsible for the regional market expansion.